CD8A and neoplasm: As shown in Figure 5C, CD8+ cell-mediated tumor lyses decreased by the addition of anti-HLA class I mAb (W6/32), but not by the addition of either an anti-HLA class II (HLA-DR) mAb or an isotype control.